Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: Factors influencing the outcome

Clinical Endocrinology

Volumn 57, Issue 5, 2002, Pages 669-676

  Manoli, I ^a   Kanaka Gantenbein, Ch ^a   Voutetakis, A ^a   Maniati Christidi, M ^a   Dacou Voutetakis, C ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; FLUDROCORTISONE; HYDROCORTISONE; SODIUM CHLORIDE;

ARTICLE; BODY GROWTH; BODY HEIGHT; BODY MASS; BONE AGE; CLINICAL ARTICLE; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; DEVELOPMENTAL STAGE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MALE; MENARCHE; PRIORITY JOURNAL; PUBERTY; SCHOOL CHILD; STEROID 21 MONOOXYGENASE DEFICIENCY; VIRILIZATION;

ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; ADRENOCORTICOTROPIC HORMONE; ADULT; BODY HEIGHT; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH; HUMANS; INFANT; INFANT, NEWBORN; MALE; PUBERTY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036422751     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2002.01645.x     Document Type: Article

References (43)

1. Appan, S., Hindmarsh, P.C. & Brook, C.G.D. (1989) Monitoring treatment in congenital adrenal hyperplasia. Archives of Disease in Childhood, 64, 1235-1239.
2. Bergstrand, C.G. (1966) Growth in congenital hyperplasia. Acta Paediatrica Scandinavica, 55, 463-472.
3. Brook, C.G.D. (1990) The management of classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinical Endocrinology, 33, 559-567.
4. Cameron, F.J., Kaymakci, B., Byrt, E.A., Ebelin, P.R., Warne, G.L. & Wark, J.D. (1995) Bone mineral density and body composition in congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 80, 2238-2243.
5. Charmandari, E., Hindmarsh, P.C., Johnston, A. & Brook, C.G.D. (2001) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Alterations in cortisol pharmacokinetics at puberty. Journal of Clinical Endocrinology and Metabolism, 86, 2701-2708.
6. Clayton, G.W. (1986) Patterns of growth from birth to maturity in infants and children with congenital adrenal hyperplasia. Acta Endocrinologica, Supplementum, 279, 295-304.
7. Cole, T.J., Freeman, J.V. & Preece, M.A. (1995) Body mass index reference curves for the UK, 1990. Archives of Disease in Childhood, 73, 25-29.
8. Cornean, R.E., Hindmarsh, P.C. & Brook, C.G.D. (1998) Obesity in 21-hydroxylase deficient patients. Archives of Disease in Childhood, 78, 261-263.
9. Cutler, G.B. & Laue, L. (1990) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. New England Journal of Medicine, 27, 1806-1813.
10. Dacou-Voutetakis, C. & Karidis, N. (1993) Congenital adrenal hyper-plasia complicated by central precocious puberty: Treatment with LHRH-agonist analogue. Annals of the New York Academy of Sciences, 687, 250-254.
11. Dacou-Voutetakis, C., Klontzo, D., Lagos, P., Tzonou, A., Katsarou, E., Antoniadis, S., Papazisis, G., Papadopoulos, G. & Matsaniotis, N. (1983) Age of pubertal development including menarche in Greek girls. Annals of Human Biology, 10, 557-564.
12. DiMartino-Nardi, J., Stoner, E., O'Connell, A. & New, M.I. (1986) The effect of treatment on final height in classical congenital adrenal hyperplasia (CAH). Acta Endocrinologica, Supplementum, 279, 305-313.
13. Dracopoulou-Vabouli, M., Maniati-Christidi, M. & Dacou-Voutetakis, C. (2001) The spectrum of molecular defects of the CYP21 gene in the Hellenic population. Variable concordance between genotype and phenotype in the different forms of congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 86 (6), 2845-2848.
14. Eugster, E.A., DiMeglio, L.A., Wright, J.C., Freidenberg, G.R., Seshari, R. & Pescovitz, O.H. (2001) Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: A meta-analysis. Journal of Pediatrics, 138, 26-32.
15. Girgis, R. & Winter, J.S.D. (1997) The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 82, 3926-3929.
16. Greulich, W.W. & Pyle, S.I. (1959) Radiographic atlas of Skeletal Development of the Hand and Wrist. 2nd Edition. Stanford, Stanford University Press.
17. Helleday, J., Siwers, B., Ritzen, M.E. & Carlstrom, K. (1993) Subnormal androgen and elevated progesterone levels in women treated for congenital virilizing 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 76 (4), 933-936.
18. Holmes-Walker, D.J., Conway, G.S., Honour, J.W., Rumsby, G. & Jacobs, H.S. (1995) Menstrual disturbance with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinical Endocrinology, 43, 291-296.
19. Jaaskelainen, J. & Voutilainen, R. (1997) Growth of patients with 21-hydroxylase deficiency: An analysis of the factors influencing adult height. Pediatrics Research, 41, 30-33.
20. Kleerekoper, M., Schiebinger, R. & Gutai, J.P. (1997) Steroid therapy for adrenal disorders - Getting the dose right. Journal of Clinical Endocrinology and Metabolism, 82 (12), 3923-3925.
21. Klingensmith, G.J., Garcia, S.C., Jones, H.W., Migeon, C.J. & Blizzard, R.M. (1977) Glucocorticoid treatment of girls with congenital adrenal hyperplasia: Effects on height, sexual maturation, and fertility. Journal of Pediatrics, 90 (6), 996-1004.
22. Laue, L., Merke, D.P., Jones, J.V., Barnes, K.M., Hill, S. & Cutler, G.B. (1996) A preliminary study of flutamide, testolactone and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 81 (10), 3535-3539.
23. Linder, B., Feuillan, P. & Chroussos, G.P. (1989) Alternate day prednisone therapy in congenital adrenal hyperplasia: Adrenal androgen suppression and normal growth. Journal of Clinical Endocrinology and Metabolism, 69 (1), 191-195.
24. Merke, D.P. & Cutler, G.B. (1997) New approaches to the treatment of congenital adrenal hyperplasia. Journal of the American Medical Association, 277 (13), 1073-1076.
25. Merke, D.P. & Cutler, G.B. (2001) New ideas for medical treatment of congenital adrenal hyperplasia. Endocrinology and Metabolism Clinics of North America, 30 (1), 121-135.
26. Migeon, C.J. & Donohue, P.A. (1991) Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. Its molecular basis and its remaining therapeutic problems. Endocrinology and Metabolism Clinics of North America, 20 (2), 277-296.
27. Migeon, C.J. & Wisniewski, A.B. (2001) Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Growth, development and therapeutic considerations. Endocrinology and Metabolism Clinics of North America, 30 (1), 193-206.
28. Mulaikal, R.M., Migeon, C.J. & Rock, J.A. (1987) Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. New England Journal of Medicine, 316, 178-182.
29. New, M.I., Gertner, J.M., Chir, B., Speiser, P.W. & del Balzo, P. (1988) Growth and final height in classical and nonclassical 21-hydroxylase deficiency. Acta Paediatrica Japonica, 30 (Suppl.), 79-88.
30. New, M.I. & Wilson, R.C. (1999) Steroid disorders in children: Congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proceedings of the National Academy of Sciences of the United States of America, 96 (22), 12790-12797.
31. Pescovitz, O.H., Cassorla, F., Comite, F., Loriaux, D.L. & Cutler, G.B. (1985) LHRH analog treatment of central precocious puberty complicating congenital adrenal hyperplasia. Annals of the New York Academy of Sciences, 458, 174-181.
32. Premawardhana, L.D.K.E., Hughes, I.A., Read, G.F. & Scanlon, M.F. (1997) Longer term outcome in females with congenital adrenal hyperplasia (CAH): The Cardiff experience. Clinical Endocrinology, 46, 327-332.
33. Sandrini, R., Jospe, N. & Migeon, C.J. (1993) Temporal and individual variations in the dose of glucocorticoid used for the treatment of salt losing congenital virilizing adrenal hyperplasia due to 21-hydroxylase deficiency. Acta Paediatrica, Supplementum, 388, 56-60.
34. Silva, N.I., Kater, C.E., de Freitas Cunha, C. & Viana, M.B. (1997) Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood, 77, 214-218.
35. Soliman, A.T.A.I., Lamki, M.A.I., Salmi, I. & Asfour, M. (1997) Congenital adrenal hyperplasia complicated by central precocious puberty: Linear growth during infancy and treatment with gonadotropin-releasing hormone analog. Metabolism, 46 (5), 513-517.
36. Styne, D.M., Richards, G.E., Bell, J.J., Conte, F.A., Morishima, A., Kaplan, S.L. & Grumbach, M.M. (1977) Growth patterns in congenital adrenal hyperplasia. Correlation of glucocorticoid therapy with stature. In: Lee, P.A., Plotnich, L.P., Kowarski, A.A. & Migeon, C.J. (eds) Congenital Adrenal Hyperplasia, 247-261. University Park Press, Baltimore.
37. Tanner, J.M., Whitehouse, R.H. & Takaishi, M. (1966) Standards from birth to maturity for height, weight, height velocity and weight velocity, British children, 1965. Archives of Disease in Childhood, 41, 454-471.
38. Tanae, A. & Hibi, I. (1988) Unresolved problems in the treatment of congenital adrenal hyperplasia. Acta Paediatrica Japonica, 30 (Suppl.), 93-98.
39. Van Wyck, J.J., Gunther, D.F., Ritzen, E.M., Wedell, A., Cutler, G.B., Migeon, C.J. & New, M.I. (1996) The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 81, 3180-3190.
40. White, P.C. & Speiser, P.W. (2000) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Reviews, 21, 245-291.
41. Young, M.C. & Hughes, I.A. (1990) Response to treatment of congenital adrenal hyperplasia in infancy. Archives of Disease in Childhood, 65, 441-444.
42. Young, M.C., Ribeiro, J. & Hughes, I.A. (1989) Growth and body proportions in congenital adrenal hyperplasia. Archives of Disease in Childhood, 64, 1554-1558.
43. Yu, A.C.M. & Grant, D.B. (1995) Adult height in women with early-treated congenital (21-hydroxylase type): Relation to body mass index in earlier childhood. Acta Paediatrica, 84, 899-903.